Role of LXRs in control of lipogenesis

Joshua R. Schultz, Hua Tu(Howard Hughes Medical Institute), Alvin Luk(Howard Hughes Medical Institute), Joyce J. Repa(Howard Hughes Medical Institute), Julio C. Medina(Howard Hughes Medical Institute), Leping Li(Howard Hughes Medical Institute), Susan W. Schwendner(Howard Hughes Medical Institute), Shelley Wang(Howard Hughes Medical Institute), Martin Thoolen(Howard Hughes Medical Institute), David J. Mangelsdorf(Howard Hughes Medical Institute), Kevin D. Lustig(Howard Hughes Medical Institute), Bei Shan(Howard Hughes Medical Institute)
Genes & Development
November 15, 2000
Cited by 1,666Open Access
Full Text

Abstract

The discovery of oxysterols as the endogenous liver X receptor (LXR) ligands and subsequent gene targeting studies in mice provided strong evidence that LXR plays a central role in cholesterol metabolism. The identification here of a synthetic, nonsteroidal LXR-selective agonist series represented by T0314407 and T0901317 revealed a novel physiological role of LXR. Oral administration of T0901317 to mice and hamsters showed that LXR activated the coordinate expression of major fatty acid biosynthetic genes (lipogenesis) and increased plasma triglyceride and phospholipid levels in both species. Complementary studies in cell culture and animals suggested that the increase in plasma lipids occurs via LXR-mediated induction of the sterol regulatory element-binding protein 1 (SREBP-1) lipogenic program.


Related Papers

No related papers found

Powered by citation graph analysis